Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer

BACKGROUND: The present study was aimed to evaluate the efficacy and safety of at least three cycles of Bevacizumab in combination with chemotherapy regimens, FOLFIRI or FOLFOX to treat liver metastatic colorectal cancer and improved response rates in these patients. MATERIALS AND METHODS: In this n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehrzad, Valiollah, Roayaei, Mahnaz, Peikar, Mohammad Saleh, Nouranian, Elham, Mokarian, Fariborz, Khani, Mohsen, Farzannia, Somaieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770632/
https://www.ncbi.nlm.nih.gov/pubmed/26962512
http://dx.doi.org/10.4103/2277-9175.175243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770632/
https://www.ncbi.nlm.nih.gov/pubmed/26962512
http://dx.doi.org/10.4103/2277-9175.175243

Ejemplares similares